Everolimus and Octreotide for Patients with Refractory and Documented Progressive Meningioma - 100459

Spotlight
Video

Everolimus and Octreotide for Patients with Refractory and Documented Progressive Meningioma

moasc has 207 videos Subscribe Here

Loading........
Description: Daniela Bota, MD of UC Irvine Health discusses a phase II clinical trial called the CEVOREM study, which focused on everolimus and octreotide in patients with meningioma. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.

Abstract 2011: A Phase II of Everolimus and Octreotide for Patients with Refractory and Documented Progressive Meningioma (CEVOREM)
Shared By : moasc
Posted on : 08/03/17
Added : 6 months ago
Category : Brain Cancer



Recommended

Nothing found.

More From moasc

Nothing found.